Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapiesRoche to acquire Poseida Therapeutics for US $9.00 per share in cash at closing, representing a total equity value of approximately US$1.0 billion Stockholders would also receive a non-tradeable contingent value right (CVR) for up to an aggregate of US $4.00 pe ...